Literature DB >> 8940755

Planning and delivering high doses to targets surrounding the spinal cord at the lower neck and upper mediastinal levels: static beam-segmentation technique executed with a multileaf collimator.

W De Neve1, C De Wagter, K De Jaeger, M Thienpont, C Colle, S Derycke, J Schelfhout.   

Abstract

BACKGROUND AND
PURPOSE: It remains a technical challenge to limit the dose to the spinal cord below tolerance if, in head and neck or thyroid cancer, the planning target volume reaches to a level below the shoulders. In order to avoid these dose limitations, we developed a standard plan involving Beam Intensity Modulation (BIM) executed by a static technique of beam segmentation. In this standard plan, many machine parameters (gantry angles, couch position, relative beam and segment weights) as well as the beam segmentation rules were identical for all patients.
MATERIALS AND METHODS: The standard plan involved: the use of static beams with a single isocenter; BIM by field segmentation executable with a standard Philips multileaf collimator; virtual simulation and dose computation on a general 3D-planning system (Sherouse's GRATIS); heuristic computation of segment intensities and optimization (improving the dose distribution and reducing the execution time) by human intelligence. The standard plan used 20 segments spread over 8 gantry angles plus 2 non-segmented wedged beams (2 gantry angles).
RESULTS: The dose that could be achieved at the lowest target voxel, without exceeding tolerance of the spinal cord (50 Gy at highest voxel) was 70-80 Gy. The in-target 3D dose-inhomogeneity was approximately 25%. The shortest time of execution of a treatment (22 segments) on a patient (unpublished) was 25 min.
CONCLUSIONS: A heuristic model has been developed and investigated to obtain a 3D concave dose distribution applicable to irradiate targets in the lower neck and upper mediastinal regions. The technique spares efficiently the spinal cord and allows the delivery of higher target doses than with conventional techniques. It can be planned as a standard plan using conventional 3D-planning technology. The routine clinical implementation is performed with commercially available equipment, however, at the expense of extended execution times.

Entities:  

Mesh:

Year:  1996        PMID: 8940755     DOI: 10.1016/0167-8140(96)01784-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Balancing control and simplicity: A variable aggregation method in intensity modulated radiation therapy planning.

Authors:  Philipp Süss; Karl-Heinz Küfer
Journal:  Linear Algebra Appl       Date:  2008-03-01       Impact factor: 1.401

2.  Empirical estimation of beam-on time for prostate cancer patients treated on Tomotherapy.

Authors:  Małgorzata Skórska; Tomasz Piotrowski
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-04

3.  Pre-segmented 2-Step IMRT with subsequent direct machine parameter optimisation - a planning study.

Authors:  Klaus Bratengeier; Jürgen Meyer; Michael Flentje
Journal:  Radiat Oncol       Date:  2008-11-06       Impact factor: 3.481

4.  Radiobiological evaluation of forward and inverse IMRT using different fractionations for head and neck tumours.

Authors:  Brigida C Ferreira; Maria do Carmo Lopes; Josefina Mateus; Miguel Capela; Panayiotis Mavroidis
Journal:  Radiat Oncol       Date:  2010-06-22       Impact factor: 3.481

5.  Interactive tele-radiological segmentation systems for treatment and diagnosis.

Authors:  S Zimeras; L G Gortzis
Journal:  Int J Telemed Appl       Date:  2012-05-07

6.  A dose-volume-based tool for evaluating and ranking IMRT treatment plans.

Authors:  Moyed M Miften; Shiva K Das; Min Su; Lawrence B Marks
Journal:  J Appl Clin Med Phys       Date:  2004-10-01       Impact factor: 2.102

7.  Initial clinical experience with ArcCHECK for IMRT/VMAT QA.

Authors:  Michalis Aristophanous; Yelin Suh; Pai C Chi; Luke J Whittlesey; Scott LaNeave; Mary K Martel
Journal:  J Appl Clin Med Phys       Date:  2016-09-08       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.